Τόμος 30 (2016) – Τεύχος 1 – Άρθρο 2 – Review of Clinical Pharmacology and Pharmacokinetics- Διεθνής Έκδοση – Volume 30 (2016) – Issue 1 – Article 2 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

Aim and Scope: The continuous rising of the coexistence between malignancies and autoimmune diseases and the expectation to underline every possible cause that connects autoimmunity and cancer.

Material and Methods: A wide retrospective study of any review article, clinical trial and research article supporting the correlation or the coexistence between autoimmune diseases and cancer using the Pubmed and Scopus data bases. 686 articles of the last decade that matched the searching criteria were studied, but only 17 were included in the study.

Conclusions: According to the recent bibliographic data, many autoimmune diseases are related to certain types of lymphomas and other malignancies. Despite the fact that the correlation between them is strong, more research is needed in order to confirm scientifically these associations and to conclude to reliable scientific conclusions.

1. Ch. Μ. Μoutsopoulos. Autoimmune diseases. Portal of Asklipian Park of Medical School of National Kapodistrian University of Athens (2015) http://panacea.med.uoa.gr/topic.aspx?id=300
2. Autoimmune diseases. National Hellenic Research Foundation (2015)http://helios-eie.ekt.gr/EIE/bitstream/10442/459/1/M01.018.07.pdf
3. Autoimmune disorders. National Library of Medicine (2015)https://www.nlm.nih.gov/medlineplus/ency/article/000816.htm
4. Descriptions of Autoimmune Diseases. American autoimmune related diseases association (2015) https://www.aarda.org/descriptions-of-diseases
5. Office a women’s health. Autoimmune diseases fact sheet. U.S. Department of health and human services (2015)http://womenshealth.gov/publications/our-publications/fact-sheet/autoimmune-diseases.html
6. Autoimmune Diseases List (2015) http://autoimmunediseaselist.com.
7. Loh KP, Kansagra A, Asik A, Ali S, Dahiya S. Paraneoplastic autoimmune hemolytic anemia in ovarian cancer: a marker of disease activity. Rare Tumors; 7(1): 5598 (2015)
8. Koyma T, Togashi K, Ueda H, et al. Paraneoplasmatic syndromes associated with ovarian neoplasms. Int J Clin Oncol; 5: 79-84 (2000)
9. Hudson CN, Curling M, Potsides P, Lowe DG. Paraneoplastic syndromes in patients with ovarian neoplasia. J R Soc Med; 86: 202-4 (1993)
10. Jones E, Tillman C. A case of hemolytic anemia relieved by removal of ovarian tumor. JAMA 128: 1225-7 (1945)
11. Norcross JW. Hematologic manifestations of malignant disease. Med Clin North Am; 47: 345-52. (1963)
12. Andre R, Duhamel G, Najman A, et al. [Autoimmune hemolytic anemia and malignant tumor of the ovary]. Presse Med; 77: 2133-6 [Article in French] (1969)
13. Gong J, Lim SW. Alopecia areata as a paraneoplastic syndrome of Hodgkin’s lymphoma: A case report. Mol Clin Oncol; 2(4): 596-598 (2014)
14. Török L, Gurbity TP, Kirschner Á and Krenács L: Panniculitis-like T-cell lymphoma clinically manifested as alopecia. Br J Dermatol 147 (4): 785-788 (2002)
15. Richmond HM, Lozano A, Jones D and Duvic M: Primary cutaneous follicle center lymphoma associated with alopecia areata. Clin Lymphoma Myeloma 8: 121-124 (2008)
16. Anderson LA, Gadalla S, Morton LM, et al: Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 125: 398-405 (2009)
17. Mani H and Jaffe ES: Hodgkin lymphoma: an update on its biology with newer insights into classification. Clin Lymphoma Myeloma 9: 206-216 (2009)
18. Mlczoch L, Attarbaschi A, Dworzak M, Gadner H and Mann G: Alopecia areata and multifocal bone involvement in a young adult with Hodgkin’s disease. Leuk Lymphoma; 46: 623-627 (2005)
19. Garg S, Mishra S, Tondon R and Tripathi K: Hodgkin’s lymphoma presenting as alopecia. Int J Trichology; 4: 169-171(2002).
20. Madani S and Shapiro J: Alopecia areata update. J Am Acad Dermatol; 42: 549-566 (2000)
21. Υang J., Ning J., Di Zhao W., Li Yan-Li, Wu Hong-Yang, and Kang-Sheng G.U.: Sarcoidosis in gastric cancer at the time of diagnosis: A case report. Oncol Lett; 9 (3): 1159-1162 (2015)
22. Bush E, Lamonica D and O’Connor T: Sarcoidosis mimicking metastatic breast cancer. Breast J; 17: 533-535 (2011)
23. Shin HC, Choe JW, Ryu HS, et al: Sarcoidosis mimicking metastatic breast cancer in Korean woman with breast cancer. Breast J 20: 198-199. (2014)
24. Kim JJ, Park JK, Wang YP, Choi SH and Jo KH: Lung cancer associated with sarcoidosis -A case report-. Korean J Thorac Cardiovasc Surg; 44: 301- 303 (2011)
25. Choi JH, Shin JA, Park HK, et al: Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer. Case Rep Oncol Med; 2014: 203027 (2014)
26. Wilgenhof S, Morlion V, Seghers AC, et al: Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF Inhibitor. Anticancer Res; 32: 1355-1359 (2012)
27. Blank N, Lorenz HM, Ho AD and Witzens-Harig M: Sarcoidosis and the occurrence of malignant diseases. Rheumatol Int (2014)
28. Kumar S, Mahajan BB, Kaur S, Singh A. Paraneoplastic dermatomyositis with carcinoma cervix: a rare clinical association. Case Rep Dermatol Med; 2014: 836Y (2014)
29. Huang, C. B. Wang, J. L. Shen, and Y. T. Chang, “Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan” Arthritis Research & Therapy; 12(2): R70 (2010)
30. L. Casciola-Rosen, K. Nagaraju, P. Plotz et al., “Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy” The Journal of Experimental Medicine; 201(4): 591–601 (2005)
31. K. Danko, A. Ponyi, A. P. Molnar, C. Andras, and T. Constantin, “Paraneoplastic myopathy” Current Opinion in Rheumatology; 21 (6): 594–598 (2009)
32. M. Levine, “Cancer and myositis: new insights into an old association” Current Opinion in Rheumatology; 18: 620– 624 (2006)
33. E. Genth, “Inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis,” Internist; 46(11): 1218–1232 (2005)
34. Airio, H. Kautiainen, and M. Hakala, “Prognosis and mortality of polymyositis and dermatomyositis patients,” Clinical Rheumatology; 25(2): 234–239 (2005)
35. Marzano AV, Tourlaki A, Cozzani E, Gianotti R, Caputo R. Pemphigus herpetiformis associated with prostate cancer. J Eur Acad Dermatol Venereol. 21(5): 696-8 (2007)
36. Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 14: 353-359 (1975)
37. Ishii K, Amagai M, Komai A et al. Desmoglein 1 and desmoglein 3 are target autoantigens in herpetiform pemphigus. Arch dermatol. 135: 943-947 (1999)
38. Zhang XD, Yang SY, Li W, Ming ZJ, Hou YL, Niu ZQ, Zhang YP. Adult Henoch-Schönlein purpura associated with small cell lung cancer: A case report and review of the literature. Oncol Lett. Jun; 5(6): 1927-1930 (2013)
39. Zurada JM, Ward KM and Grossman ME: Henoch-Schönlein Purpura associated with malignancy in adults. J Am Acad Dermatol 55 (5 Suppl): 65-70 (2006)
40. Fain O, Hamidou M, Cacoub P, et al: Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum; 57: 1473-1480 (2007)
41. Podjasek JO, Wetter DA ,Pittelkow MR, et al: Henoch-Schönlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol 92: 388-392 (2012)
42. Flynn AN, du Prey B, Al Ardati H, et a1: Adult onset malignancy-associated Henoch-Schönlein purpura. Scan J Rheumatol 40: 325-326 (2011)
43. Weiler-Bisig D, Ettlin G, Brink T, et al: Henoch-Schönlein purpura associated with esophagus carcinoma and adenocarcinoma of the lung. Clin Nephrol; 63: 302-304 (2005)
44. Georgakopoulou EA, Achtari MD, Achtaris M, Foukas PG, Kotsinas A. Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol; 2012: 759626 (2012)
45. M. A. Gonzalez-Moles, C. Scully, and J. A. Gil-Montoya, “Oral lichen planus: controversies surrounding malignant transformation” Oral Diseases 14(3): 229–243 (2008)
46. G. Lodi, C. Scully, M. Carrozzo et al., “Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology; 100(2): 164–178 (2005)
47. F. A. Sousa, T. C. Paradella, Y. R. Carvalho, and L. E. Rosa, “Immunohistochemical expression of PCNA, p53, bax and bcl-2 in oral lichen planus and epithelial dysplasia” Journal of Oral Science: 51 (1): 117–121.(2009)
48. M. A. Gonzalez-Moles, C. Bascones-Ilundain, J. A. Gil Mon- ´ toya, I. Ruiz-Avila, M. Delgado-Rodriguez, and A. BasconesMart´ınez, “Cell cycle regulating mechanisms in oral lichen planus: molecular bases in epithelium predisposed to malignant transformation.” Archives of Oral Biology; 51 (12): 1093–1103. (2006)
49. R. A. Safadi, S. Z. A. Jaber, H. M. Hammad, and A. A. H. Hamasha, “Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study.” Archives of Oral Biology; 55(6): 454–461 (2010)
50. Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg; 79(1): 219-24 (2005)
51. Perrot M, Liu J, Bril V, McRae K, Bezjak A, Keshavjee SH. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg: 74:1658–62 (2002)
52. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg; 76:878–85 (2003)
53. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer; 94: 624–32 (2002)
54. Gelfand JM,; Berlin J,; Van Voorhees A,; Margolis DJ . Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol; 139: 1425–9 (2003)
55. Doody MM, Linet MS, Glass AG, Friedman GD, Pottern LM, Boice JD Jr et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control; 3: 449–56 (1992)
56. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest; 115: 798–812 (2005)
57. Lelievre JD, Sacre K, Adle-Biassette H, Molinier-Frenkel V, Gaulard P, Papo T Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol 52: 24–7 (2005)
58. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc; 9: 136–9 (2004)
59. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control; 15: 419–28 (2004)
60. Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, Cheng YH, Kao CH. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid; 23 (7): 879-84 (2013)
61. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. Br J Cancer: 102: 1397–1399 (2010)
62. Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, et al. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest; 30: 734–738 (2007)
63. Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol; 154: 645–649 (2006)
64. Pazaitou-Panayiotou K, Perros P, Boudina M, Siardos G, Drimonitis A, Patakiouta F,. et al. Mortality from thyroid cancer in patients with hyperthyroidism: the Theagenion Cancer Hospital experience. Eur J Endocrinol; 159: 799–803 (2008)
65. Basha J, Appasani S, Dixit P, Vaiphei K, Kartarsingh, Kochhar R. Celiac disease complicated by lymphoma. Trop Gastroenterol. Jan-Mar; 35(1):55-6 (2014)
66. Elfström P, Granath F, Ekström Smedby K, Montgomery SM, et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst. 103(5): 436-44 (2011)
67. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut.; 48 (4): 526-35 (2001)
68. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut; 35: 950–4 (1994)
69. Radhakrishnan S, Zubaidi G, Daniel M, et al. Ulcerative colitis in Oman: a prospective study of the incidence and disease pattern from 1987 to 1994. Digestion; 58: 266–70 (1997)
70. Dong L, Chen Y, Masaki Y, Okazaki T, Umehara H. Possible Mechanisms of Lymphoma Development in Sjögren’s Syndrome. Curr Immunol Rev. 9(1): 13-22 (2013)
71. Li XY, Wu ZB, Ding J, et al. Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjögren’s syndrome. Biochem Biophys Res Commun; 422 (2): 238-44 (2012)
72. Youinou P, Pers JO. Latest update on the primary Sjogren’s syndrome. Presse Med; 41(9 Pt 2): e437-9 (2012)
73. Ramos-Casals M, Munoz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol; 36(7): 1442-8 (2009)
74. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren’s syndrome. J Autoimmun; 39(1-2): 103-11 (2012)
75. Kallenberg CG, Vissink A, Kroese FG, Abdulahad WH, Bootsma H. What have we learned from clinical trials in primary Sjogren’s syndrome about pathogenesis? Arthritis Res Ther; 13(1): 205 (2011)
76. Rajan A, Kotlyar D, Giaccone G. Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. J Thorac Oncol. Oct; 8(10): e87-8 (2013)
77. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol; 5(10 Suppl 4): S260–5 (2010)
78. Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol; 8: 199–202 (2011)
79. Boussios S, Kostadima V, Batistatou A, Tourkantonis I, Fotopoulos G, Argyropoulou MI, Pavlidis N. Neuroendocrine cell carcinoma of unknown primary arising in long standing history of multiple sclerosis. Case Rep Oncol Med. 2015: 135976 (2015)
80. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 135 (Pt 10): 2973-9 (2012).
81. M.-L. Sumelahti, E. Pukkala, and M. Hakama, “Cancer incidence in multiple sclerosis: a 35-year follow-up” Neuroepidemiology; 23(5): 224–227 (2004)
82. C. Lebrun, M. Debouverie, P. Vermersch et al., “Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis,” Multiple Sclerosis:14(3): 399–405 (2008)
83. E. Handel, A. Joseph, and S. V. Ramagopalan, “Multiple sclerosis and lung cancer: an unexpected inverse association” QJM; 103 (8): 625–626 (2010)
84. M. Landgren, O. Landgren, G. Gridley, G. M. Dores, M. S. Linet, and L. M. Morton, “Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans” Cancer; 117(6): 1163–1171 (2011)
85. Cao L, Tong H, Xu G, Liu P, Meng H, Wang J, Zhao X, Tang Y, Jin J. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One; 17;10 (2015)
86. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 165: 2337–2344 (2005)
87. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun; 42: 130–135(2013)
88. Huang HB, Jiang SC, Han J, Cheng QS, Dong CB, Pan CM. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol. 140: 1067–1073 (2014)
89. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 19: 887–894 (2008)
90. Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer 131:2126–2133 (2012)
91. Feldt-Rasmussen U., Rasmussen A.K: Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) 9: 109-117 (126) (2010)
92. Stoikidou M., Pavara M., Zisopoulos A., Antouli-Anagnostopoulou F., Vardaki Z., Iatrakis G., Hashimoto’s Thyroiditis: A distinctive autoimmune disorder. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 17: 139-152 (2003)
93. Catherine Kapnopoulou, Nikolaos Thalassinos, Despina Desso, Maria Venetikou, Fragiski Anthouli-Anagnostopoulou: Correlation Of Hashimoto’s Thyroiditis with Thyroid Cancer : is it a random Coexistence or a particular risk factor? Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 29: 5-12 (2015)